Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells.
The efficiency of dendritic cells (DC) as immunotherapeutic vaccines critically depends on optimal delivery of target Ags. Although DC modified by subgroup C type 5 recombinant adenoviruses (rAd5) provide encouraging results, their clinical application is hampered by the need for high viral titers to achieve sufficient gene transfer, due to the lack of the Ad5 fiber receptor. We now demonstrate that rAd5 carrying subgroup B Ad fibers are up to 100-fold more potent than classical rAd5 for gene transfer and expression in human DC, rAd5 with a type 35 fiber (rAd5F35) being the most efficient vector. This improvement relates to a greater and faster virus entry and to an increased transgene expression especially following DC maturation. Furthermore, these new vectors possess enhanced synergistic effects with other activation signals to trigger DC maturation. Consequently, rAd5F35-infected DC engineered to express the gp100 melanoma-associated Ag largely exceed rAd5-infected DC in activating gp100-specific CTL. Finally, the DC infection pattern of rAd5F35 is fully conserved when DC are in the vicinity of primary skin-derived fibroblasts, suggesting this vector as a candidate for in vivo targeting of DC. Thus, subgroup B fiber-modified rAd5 constitute a major breakthrough in the exploitation of ex vivo rAd-targeted DC as clinically relevant vaccines and may also be suitable for in vivo genetic modification of DC.
Rea
D
D
Department of Immunohematology and Blood Bank, Leiden University Medical Center, Leiden, The Netherlands.
Havenga
M J
MJ
van Den Assem
M
M
Sutmuller
R P
RP
Lemckert
A
A
Hoeben
R C
RC
Bout
A
A
Melief
C J
CJ
Offringa
R
R
D000256:Adenoviridae / Q000235:genetics* / Q000276:immunology; D000276:Adjuvants, Immunologic / Q000235:genetics / Q000627:therapeutic use; D017951:Antigen Presentation / Q000235:genetics*; D000956:Antigens, Viral / Q000235:genetics / Q000627:therapeutic use; D002213:Capsid / Q000235:genetics* / Q000276:immunology / Q000627:therapeutic use; D036022:Capsid Proteins; D002454:Cell Differentiation / Q000235:genetics / Q000276:immunology; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology* / Q000821:virology*; D004357:Drug Synergism; D015967:Gene Expression Regulation, Viral / Q000276:immunology; D018014:Gene Transfer Techniques; D005822:Genetic Vectors / Q000276:immunology / Q000627:therapeutic use; D049452:Green Fluorescent Proteins; D006801:Humans; D008070:Lipopolysaccharides / Q000494:pharmacology; D008164:Luminescent Proteins / Q000096:biosynthesis / Q000235:genetics; D009000:Monocytes / Q000166:cytology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000378:metabolism / Q000821:virology; D014161:Transduction, Genetic / Q000379:methods*; D019076:Transgenes / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000956:Antigens, Viral; D036022:Capsid Proteins; D008070:Lipopolysaccharides; D008164:Luminescent Proteins; C018315:hexon capsid protein, Adenovirus; D049452:Green Fluorescent Proteins